Send to a Friend Font Size: Increase Decrease

OrbiMed Advisors

OrbiMed Advisors's Portfolio

Last Updated on 5/16/11 @ 11:13am

Ticker	# of Shares	Price	Value
	73,114,592	$195.32	$14,280,742,110
	22,362,850	$195.32	$4,367,911,862
	17,233,668	$195.32	$3,366,080,034
	14,567,176	$195.32	$2,845,260,817
	9,033,726	$195.32	$1,764,467,363
	8,998,338	$195.32	$1,757,555,379
	8,322,140	$195.32	$1,625,480,385
	8,009,729	$195.32	$1,564,460,269
	7,619,135	$195.32	$1,488,169,449
View Additional Portfolio Information »

http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.

Login to help us fill in information about this entity.

View Older Stories View More Recent Stories

May 9, 2019 07:25AM Alpine Immune Sciences Provides Corporate Update and Reports First Quarter 2019 Financial Results
May 7, 2019 08:00AM Kyn Therapeutics Strengthens Leadership Team with Key Appointments
Apr 29, 2019 01:11PM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 29, 2019 01:11PM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 24, 2019 06:17PM Form 4 Turning Point Therapeuti For: Apr 22 Filed by: ORBIMED ADVISORS LLC
Apr 24, 2019 05:29PM Form SC 13D Turning Point Therapeuti Filed by: ORBIMED ADVISORS LLC
Apr 24, 2019 09:00AM Emendo Biotherapeutics Enters Into Licensing Option Agreement With Takeda for its OMNI Nuclease Program
Apr 19, 2019 02:20PM Form SC 13G X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Apr 16, 2019 07:04PM Form 3 Turning Point Therapeuti For: Apr 16 Filed by: ORBIMED ADVISORS LLC
Apr 16, 2019 08:38AM PlacementTracker Publishes Q1 2019 PIPE and Private Placement Markets League Tables
Apr 9, 2019 01:45PM Form SC 13D/A Tricida, Inc. Filed by: ORBIMED ADVISORS LLC
Apr 4, 2019 05:01PM Form SC 13D/A Xtant Medical Holdings, Filed by: ORBIMED ADVISORS LLC
Apr 3, 2019 01:07PM Form 4 Xtant Medical Holdings, For: Apr 01 Filed by: ORBIMED ADVISORS LLC
Apr 1, 2019 08:30AM Xtant Medical Announces Amendments and Extension of Credit Facility
Mar 25, 2019 05:13PM Form SC 13D/A resTORbio, Inc. Filed by: ORBIMED ADVISORS LLC
Mar 19, 2019 04:58PM Form SC 13D/A X4 Pharmaceuticals, Inc Filed by: ORBIMED ADVISORS LLC
Mar 18, 2019 07:30AM Alpine Immune Sciences Provides Corporate Update and Reports Full Year 2018 Financial Results
Mar 18, 2019 07:00AM Imara Closes a $63MM Series B Cross-Over Financing
Mar 18, 2019 03:42AM Arix Bioscience plc: Arix Co-leads $63 Million Series B Investment Round for Imara
Mar 12, 2019 05:21PM Form SC 13D/A Ascendis Pharma A/S Filed by: ORBIMED ADVISORS LLC
Mar 12, 2019 04:05PM Natera Reports Fourth Quarter and Fiscal Year 2018 Financial Results
Mar 11, 2019 03:34AM Sinovac’s Poison Pill Attempt Stopped by Court Orders
Mar 10, 2019 11:34PM Sinovac’s Poison Pill Attempt Stopped by Court Orders
Mar 8, 2019 06:28PM Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares
Mar 1, 2019 04:02PM Form SC 13D/A Clementia Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 28, 2019 05:28PM Form SC 13D AVEDRO INC Filed by: ORBIMED ADVISORS LLC
Feb 27, 2019 08:20AM MeiraGTx Holdings plc (MGTX) Reports $80 Million Private Placement of Ordinary Shares
Feb 27, 2019 08:15AM MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
Feb 27, 2019 08:15AM MeiraGTx Announces $80 Million Private Placement of Ordinary Shares
Feb 22, 2019 05:15PM Sinovac Determines Trigger Event Occurred Under Rights Agreement
Feb 21, 2019 05:13PM Form SC 13G Harpoon Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 20, 2019 05:23PM Form SC 13D Alector, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 14, 2019 04:48PM Form 13F-HR ORBIMED ADVISORS LLC For: Dec 31
Feb 14, 2019 08:00AM Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Feb 14, 2019 08:00AM Passage Bio Launches with $115.5 Million Series A to Develop AAV-Delivered Therapeutics to Treat Rare Monogenic CNS Diseases
Feb 13, 2019 06:15AM Form SC 13G/A Insys Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Clovis Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A PUMA BIOTECHNOLOGY, INC. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A eHealth, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Deciphera Pharmaceutical Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A FLUIDIGM CORP Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Wright Medical Group Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A IOVANCE BIOTHERAPEUTICS, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A IMMUNOMEDICS INC Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G/A Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:15AM Form SC 13G Inspire Medical Systems, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A Audentes Therapeutics, Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A ACHILLION PHARMACEUTICAL Filed by: ORBIMED ADVISORS LLC
Feb 13, 2019 06:14AM Form SC 13G/A ASSEMBLY BIOSCIENCES, Filed by: ORBIMED ADVISORS LLC

View More Recent Stories View Older Stories

Nasdaq		15000.33
	+57.68	(+0.39%)

S&P 500		4486.55
	+7.02	(+0.16%)

Market Snapshot

Free News Feed